

Date: 1 March 2024



To,
Manager - Listing Compliance
National Stock Exchange of India Limited
'Exchange Plaza',
C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai-400051

Ref: Application for obtaining approval under Regulation 37 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") for the scheme of amalgamation of Cohance Lifesciences Limited into and with Suven Pharmaceuticals Limited under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013.

Dear Sir/Madam,

In connection with the captioned application, the financial details of Cohance Lifesciences Limited for the previous 3 years as per the audited statement of Accounts is set out below:

Name of the Company: **Cohance Lifesciences Limited**

(Rs. in Crores except per share data)

Particulars	As per last Audited Financial period (9M ended 31 December 2023)	As per last Audited Financial year 22-23	1 year prior to the last Audited Financial Year 21-22 ⁽¹⁾	2 years prior to the last Audited Financial Year 20-21
Equity Paid up Capital	145.84	145.84	145.84	145.84
Reserves and surplus	1,253.70	697.98	443.62	427.98
Carry forward losses	-	-	-	-
Net Worth	1,399.54	843.82	589.46	573.82
Miscellaneous Expenditure	-	-	-	-
Secured Loans	446.51	169.32	124.62	-
Unsecured Loans ⁽²⁾	374.18	432.68	299.15	274.05
Fixed Assets ⁽³⁾	1,336.74	972.53	975.31	-
Income from Operations	891.90	745.87	751.15	0.62
Total Income	912.89	756.27	754.98	9.18
Total Expenditure	801.07	703.31	720.22	11.92
Profit before Tax	111.82	52.97	34.77	(2.76)
Profit after Tax	83.50	37.76	16.19	0.09
Cash profit ⁽⁴⁾	171.90	77.81	60.44	0.09
EPS ⁽⁵⁾	0.24	0.39	0.21	0.01
Book value ⁽⁶⁾	95.96	57.86	40.42	39.34



Cohance Lifesciences Limited
Regd. Office: # 215 Atrium, "C" Wing,
8th Floor, 819-821, Andheri Kurla Road,
Chakala, Andheri East, Chakala MIDC,
Mumbai, Maharashtra - 400093.
CIN: U24100MH2020PLC402958
T 022 65139999
E reachus@cohance.com
W www.cohance.com

Corporate Office :
Unit No - 202, 2nd Floor, B Wing,
Galaxy Towers, Plot No-1,
Hyderabad Knowledge City,
TSIC, Raidurg, Panmaktha,
Serilingampally Mandal,
Rangareddi Dist., Hyderabad-500 081,
Telangana, India.
T +91 40 44758595

Notes:

1. Extracted from audited financial statements for the financial year ended March 31, 2023, as the figures for the financial year ended March 31, 2022, were regrouped/ restated in the audited financial statements for the financial year ended March 31, 2023
2. Excluding lease liabilities recognised as per Ind AS 116 “Leases.”
3. Includes Property, plant and equipment, capital work-in-progress, right-of-use assets, goodwill, intangible assets under development and other intangible assets.
4. Cash profit = Profit After Tax + Depreciation and Amortisation Expenses + Employee stock option expenses (ESOP)
5. Not annualised for the December Year-to-Date.
6. Book value per share = Net worth as per books / Number of shares as at the end of the period.

Note: The financials should not be more than 6 months old. In such cases additional column may be added to provide the latest audited financials.

For Cohance Lifesciences Limited
G. Praneeth Abhishek



Company Secretary
Membership No. 35583
Place: Hyderabad

